Araştırma Çıktıları
Permanent URI for this communityhttps://hdl.handle.net/11443/931
Browse
4 results
Search Results
Item High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis(BMC, 2021-01-01) Affatato, Oreste; Moulin, Thiago C.; Pisanu, Claudia; Babasieva, Victoria S.; Russo, Marco; Aydinlar, Elif I.; Torelli, Paola; Chubarev, Vladimir N.; Tarasov, Vadim V.; Schioeth, Helgi B.; Mwinyi, JessicaBackground: Migraine and depression are highly prevalent and partly overlapping disorders that cause strong limitations in daily life. Patients tend to respond poorly to the therapies available for these diseases. OnabotulinumtoxinA has been proven to be an effective treatment for both migraine and depression. While many studies have addressed the effect of onabotulinumtoxinA in migraine or depression separately, a growing body of evidence suggests beneficial effects also for patients comorbid with migraine and depression. The current meta-analysis systematically investigates to what extent onabotulinumtoxinA is efficient in migraineurs with depression. Methods: A systematic literature search was performed based on PubMed, Scopus and Web of Science from the earliest date till October 30th, 2020. Mean, standard deviation (SD) and sample size have been used to evaluate improvement in depressive symptoms and migraine using random- effects empirical Bayes model. Results: Our search retrieved 259 studies, eight of which met the inclusion criteria. OnabotulinumtoxinA injections administered to patients with both chronic migraine and major depressive disorder led to mean reduction of - 8.94 points (CI {[} - 10.04,- 7.84], p < 0.01) in the BDI scale, of - 5.90 points (CI {[} - 9.92,- 1.88], p < 0.01) in the BDI-II scale and of - 6.19 points (CI {[} - 9.52,- 2.86], p < 0.01) in the PHQ-9 scale, when evaluating depressive symptoms. In the case of the migraine-related symptoms, we found mean reductions of - 4.10 (CI {[} - 7.31,- 0.89], p = 0.01) points in the HIT6 scale, - 32.05 (CI {[} - 55.96,- 8.14], p = 0.01) in the MIDAS scale, - 1.7 (CI {[} - 3.27,- 0.13], p = 0.03) points in the VAS scale and of - 6.27 (CI {[} - 8.48,- 4.07], p < 0.01) migraine episodes per month. Comorbid patients showed slightly better improvements in BDI, HIT6 scores and migraine frequency compared to monomorbid patients. The latter group manifested better results in MIDAS and VAS scores. Conclusion: Treatment with onabotulinumtoxinA leads to a significant reduction of disease severity of both chronic migraine and major depressive disorder in patients comorbid with both diseases. Comparative analyses suggest an equivalent strong effect in monomorbid and comorbid patients, with beneficial effects specifically seen for certain migraine features.Item The relation of sexual function to migraine-related disability, depression and anxiety in patients with migraine(BMC, 2014-01-01) Eraslan, Defne; Dikmen, Pinar Yalinay; Aydinlar, Elif Ilgaz; Incesu, CemDepression and anxiety are two phenomena that affect quality of life as well as sexual function. Depression and anxiety levels are reported to be high in migraine sufferers. We aimed to understand whether sexual function in women with migraine was associated to migraine-related disability and frequency of migraine attacks, and whether this relationship was modulated by depressive and anxiety symptoms. As migraine is more commonly seen in females, a total of 50 women with migraine were included. The diagnosis of migraine with or without aura was confirmed by two specialists in Neurology, according to the second edition of International Headache Society (IHS) International Classification of Headache Disorders (ICHD-II) in 2004. Migraine disability assessment scale score, female sexual function index scores, Beck depression inventory score and Beck anxiety inventory scores. Mean MIDAS score was 19.3 +/- 12.8, and mean number of migraine attacks per month were 4.3 +/- 2.7. Mean Female Sexual Function Index score was 20.9 +/- 5.9 and 90\% of patients had sexual dysfunction. Sexual dysfunction was not related to MIDAS score or frequency and severity of attacks. No relationship between sexual function and anxiety was found, whereas severity of depressive symptoms was closely related to sexual function. Depressive symptoms affected all dimensions of sexual function, except for pain. Sexual dysfunction seemed to be very common in our patients with migraine, while not related to migraine related disability, frequency of attacks and migraine severity or anxiety. The most important factor that predicted sexual function was depression, which was also independent of disease severity and migraine related disability. While future larger scale studies are needed to clarify the exact relationship, depressive and sexual problems should be properly addressed in all patients with migraine, regardless of disease severity or disability.Item Association between somatic amplification, anxiety, depression, stress and migraine(BMC, 2013-01-01) Yavuz, Burcu Goksan; Aydinlar, Elif Ilgaz; Dikmen, Pinar Yalinay; Incesu, CemThe aim of this study is to investigate the associations between migraine related disability and somatosensory amplification, depression, anxiety, and stress. Fifty-five migraine patients who applied to the outpatient unit of the Neurology Department of Acibadem University School of Medicine, Maslak Hospital in Istanbul, Turkey, and twenty-eight subjects without migraine were recruited for the study. The participants were asked to complete a sociodemographic form, Migraine Disability Assessment Scale (MIDAS), Depression Anxiety Stress Scale, Somatosensory Amplification Scale (SSAS). Somatosensory amplification scores were significantly higher in the migraineurs than in the control group (29.85+/-6.63 vs 26.07+/-7.1Item The Acute Treatment of Migraine Attack in Adults and American Headache Society Evidence Assessment of Migraine Pharmacotherapies(TURKISH NEUROLOGICAL SOC, 2016-01-01) Dikmen, Pinar YalinayMigraine is a common, the primary debilitating and recurring headache disorder. The main purpose migraine acute pharmacology is to reduce the impact and disability caused by the attack of migraine. This review primarily reminds clinical pearls in acute treatment of migraine and also summarizes the American Headache Society Evidence Assessment of Migraine Pharmacotherapies that published last year.